Skip to main content
UK biotech gains $8.7M in funding for CAR-T therapy development

Cell Medica, a UK-based biotech firm, received an $8.7 million grant from the Cancer Prevention & Research Institute of Texas that will allow the firm to develop an off-the-shelf chimeric antigen receptor T-cell therapy that engineers a donor's immune cells to detect cancer antigens in patients with hematologic cancers and solid tumors.

Full Story: